A clinical trial of KAYO-1609 in patients with genetically-defined cancers
Latest Information Update: 21 Sep 2023
At a glance
- Drugs KAYO 1609 (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 21 Sep 2023 New trial record
- 18 Sep 2023 According to a KayoThera media release, the company plans initiate IND-enabling studies of KAYO-1609 in the third quarter of 2023 and anticipates filing an IND application with the FDA by the end of 2024. Following acceptance of the IND, the company plans to initiate a human clinical trial of KAYO-1609 in patients with genetically-defined cancers.